



VOXNEURO INNOVATION HIGHLIGHT



COMPANY OVERVIEW

VoxNeuro is positioned to globally change the way brain health is managed and treated. Backed by more than 30 years of peer-reviewed scientific research, the neurotechnology scores multiple core cognitive functions to support proactive brain health, informed clinical decision-making and customized care. By analyzing the electrical activity of the brain, VoxNeuro scores its cognitive performance in memory, information processing, attention & concentration.

VoxNeuro is headquartered at McMaster Innovation Park in Hamilton, ON, Canada.

LOCATION: HAMILTON, ON

TECHNOLOGY



Data Centre and Cloud

Dr. Kyle I. Ruiten, VP of Clinical & Scientific Affairs

kyle@voxneuro.com
voxneuro.com

Rick Penwarden, Sr. Manager, Marketing

rick.penwarden@cengn.ca
cengn.ca/projects

SUBJECTIVE ASSESSMENTS LEAD TO A HIGH MARGIN OF ERROR IN DIAGNOSES

The gold standard of cognitive assessment today is based on observed behaviour and patient self-reporting, not biometrics. This leads to a large margin of error in diagnosis and poor patient outcomes. With our growing community population, there is a widening gap for neurological services in Canada. Many times, patients are over-treated and over-tested and this can place a substantial burden on our healthcare system and subject the patient to unnecessary harm.

THE COGNITIVE HEALTH ASSESSMENT™ AND COGNITIVE HEALTH ASSESSMENT MANAGEMENT PLATFORM™

VoxNeuro developed their neurotechnology to complement clinical protocols, providing valuable data to the diagnostic process and helping inform treatment. When treatment is undertaken, repeat assessments track changes in a patient's cognitive scores to monitor their progress and validate the efficacy of treatment, helping healthcare providers maximize patient outcomes and expedite recovery. VoxNeuro's solution can be used for proactive monitoring throughout aging, reactive evaluation of an injury or disorder, to monitor high-risk professionals such as athletes and first responders, and to support data-driven industries such as pharma.

VALIDATING AND SCALING AT CENGN

Looking to launch their new Cognitive Health Assessment Platform™ (CHAMP), VoxNeuro successfully validated that their application can handle the anticipated level of concurrent users for commercial launch. The organization also scaled their platform on QA processors without significantly impacting its performance and proved their platform can accommodate different user types. VoxNeuro made great improvements to their product and CENGN was delighted to provide them with the infrastructure required for testing.

“With CENGN, we confirmed our platform could scale to a capacity that exceeded our expectations and pinpointed areas of optimization, improving the platform before its commercial launch.”

Dewey Mai

Technical Director of Product Development, AI & Technology, VoxNeuro

